Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teropavimab and Zinlirvimab in Viremic HIV
NCT04250636Phase 1Completed
- Sponsor
- The Rockefeller University
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Teropavimab and zinlirvimab in human immunodeficiency virus type 1 infection (HIV-1), sponsored by The Rockefeller University. Primary endpoints: Grade 3 and Serious Adverse Events at 24 weeks, Peak Concentration at 24 weeks and 3 more. Started Oct 2020; status: completed.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04250636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250636.